Trials
Search / Trial NCT06437691

Effect of Stent Placement on Short Term Survival of Left Sided Obstructive Colorectal Cancers

Launched by YASIR MUSA KESGIN, MD · May 25, 2024

Apply for Trial

Trial Information

Current as of March 13, 2025

Completed

Keywords

Obstruction, Bridge To Surgery

ClinConnect Summary

Patients who applied to emergency department of a single tertiary referral center between January 2016 and December 2020 and diagnosed as left sided obstructive colorectal cancer were included in this retrospective study. All patients were equal or older than 18 years and histopathologically found to have primary colorectal malignant neoplasms.

Patients were excluded from the analysis if they met any of the following criteria:

* Who underwent emergency surgery due to unsuccessful stent application intervention or stent-related complications developed,
* Those with middle and lower rectum ...

Gender

ALL

Eligibility criteria

  • Inclusion Criteria:
  • • All patients were equal or older than 18 years and histopathologically found to have primary colorectal malignant neoplasms and diagnosed as left sided (descending colon, sigmoid colon and upper rectum) obstructive colorectal cancer were included
  • Exclusion Criteria:
  • • Who underwent emergency surgery due to unsuccessful stent placement intervention
  • • Who underwent emergency surgery due to stent-related complications
  • • Those with middle and lower rectum tumors
  • • Those received neoadjuvant treatment,
  • • Patients have perforation,
  • • Who underwent subtotal or total colectomy (as a result of colon ischemia in the cecum, microperforation, etc.),
  • • Who has a recurrent disease or metastasis.

Trial Officials

Ahmet Sürek

Study Chair

Bakırköy Dr. Sadi Konuk Training and Research Hospital

About Yasir Musa Kesgin, Md

Dr. Yasir Musa Kesgin, MD, is a distinguished clinical trial sponsor with extensive expertise in advancing medical research and innovation. With a strong background in clinical medicine, Dr. Kesgin is dedicated to the development of novel therapeutic approaches and the evaluation of new treatment modalities. His leadership in clinical trials is characterized by a commitment to rigorous scientific standards, patient safety, and ethical conduct, ensuring that studies are conducted with the utmost integrity. Through collaboration with multidisciplinary teams, Dr. Kesgin aims to contribute to the enhancement of healthcare outcomes and the translation of research findings into clinical practice.

Locations

People applied

Timeline

First submit

Trial launched

Trial updated

Estimated completion

Not reported

Discussion 0